Women’s Health for FNP Boards: High-Yield Review and Exam Tips

Women's Health · 5 min read · July 13, 2026

Women’s health FNP board review study notes

Women’s Health for FNP Boards: The High-Yield Review You Actually Need

Women’s health questions on the FNP boards are rarely difficult because of one obscure fact. They become difficult when several reasonable options appear in the same question and you must identify the safest contraceptive, correct screening interval, most appropriate treatment, or next clinical step.

Whether you are preparing for the AANP or ANCC FNP certification exam, your goal should not be to memorize every women’s health guideline in isolation. You need to recognize the patterns that repeatedly appear in board-style questions:

Which contraceptive is safest for this patient?
Does this patient have a contraindication to estrogen?
Is cervical or breast cancer screening indicated?
Which STI tests should be ordered?
Does a patient with menopausal symptoms need systemic or local treatment?
Which finding changes the plan?

This high-yield women’s health FNP board review focuses on the clinical decisions you are most likely to encounter: contraception, preventive screening, STI testing, menopause management, and the board-exam traps hidden inside each topic.

How the FNP Boards Test Contraception

Contraception questions usually begin with a patient characteristic that makes one option safer—or more dangerous—than the others.

Before selecting a method, look for:

Age
Smoking status
Migraine with or without aura
Blood pressure
History of venous thromboembolism
Current or previous breast cancer
Breastfeeding or postpartum status
Adherence concerns
Menstrual bleeding preferences
Current pelvic infection
Need for emergency contraception

The Centers for Disease Control and Prevention classifies contraceptive safety using the U.S. Medical Eligibility Criteria for Contraceptive Use, often abbreviated as U.S. MEC:

Category 1: No restriction
Category 2: Benefits generally outweigh risks
Category 3: Risks usually outweigh benefits
Category 4: Unacceptable health risk; do not use the method

Understanding these categories is more useful than memorizing a disconnected list of “good” and “bad” contraceptives.

Combined Hormonal Contraceptives: Know When Estrogen Is Unsafe

Combined hormonal contraceptives contain both estrogen and a progestin. This category includes:

Combined oral contraceptive pills
The contraceptive patch
The vaginal ring

They primarily prevent pregnancy by suppressing ovulation, but the estrogen component increases thrombotic and cardiovascular risk in certain patients.

High-yield contraindications to combined hormonal contraception

For FNP board questions, avoid combined hormonal contraception when the patient has a U.S. MEC Category 4 condition, including:

Migraine with aura
Current breast cancer
Severe hypertension of at least 160/100 mm Hg
Certain high-risk histories of deep vein thrombosis or pulmonary embolism
Age 35 or older while smoking at least 15 cigarettes per day
Certain serious vascular, hepatic, or cardiovascular conditions

Smoking fewer than 15 cigarettes per day after age 35 is generally considered Category 3 rather than Category 4, but board questions will typically expect you to choose a safer non-estrogen method. Migraine with aura is a contraindication to combined hormonal contraception regardless of whether the patient is younger or older than 35.

Board-style example

A 38-year-old patient smokes one pack of cigarettes per day and requests oral contraception. She has regular cycles and no history of pregnancy complications.

The safest answer is not a combined oral contraceptive. Select a progestin-only or nonhormonal option instead.

Board pearl

When a patient has multiple medical conditions, do not begin by asking which contraceptive is most convenient. Begin by eliminating the options that create an unacceptable risk.

Progestin-Only Pills: The Timing Rule Has an Important Exception

Progestin-only pills can be useful for patients who should not use estrogen. They are also frequently considered during breastfeeding, although postpartum timing and individual medical risks still matter.

A common board-prep statement is that every progestin-only pill must be taken within the same three-hour window. That is no longer accurate because the timing instructions depend on the formulation.

Norethindrone or norgestrel progestin-only pills

A pill is considered missed when it is taken more than three hours late. The patient should:

Take the pill as soon as possible.
Continue the remaining pills at the usual time.
Use condoms or abstain from intercourse until pills have been taken correctly for two consecutive days.
Consider emergency contraception when appropriate.

Drospirenone progestin-only pills

Drospirenone pills have a wider timing window. One late or missed pill within 48 hours generally does not require backup contraception. Backup contraception is recommended when two or more consecutive active pills have been missed.

This distinction is exactly the kind of updated detail that can turn a familiar-looking question into a missed board question.

Depot Medroxyprogesterone Acetate: Remember the Bone Warning

Depot medroxyprogesterone acetate, commonly known as Depo-Provera or DMPA, is a progestin injection administered at regular intervals.

The most testable safety concern is its FDA boxed warning regarding loss of bone mineral density. Bone loss may increase with longer use and may not be completely reversible in every patient. The FDA labeling advises against using DMPA as a long-term method beyond two years unless other options are considered inadequate.

Additional counseling commonly includes the possibility of:

Irregular or prolonged bleeding
Amenorrhea
Weight changes
A delay in the return of fertility after discontinuation

The board question may not ask whether DMPA is “good” or “bad.” It may ask which counseling statement is most important for a patient with osteoporosis risk factors or concerns about future pregnancy timing.

IUDs and Implants: Long-Acting Does Not Mean Complicated

Long-acting reversible contraceptives, or LARCs, include intrauterine devices and the etonogestrel implant. They are highly effective and remove the need for daily adherence.

Levonorgestrel-releasing IUD

The hormonal IUD is often a strong choice for a patient who wants highly effective contraception and would benefit from reduced menstrual bleeding.

Copper IUD

The copper IUD contains no hormones. It may be appropriate for patients who prefer or require a nonhormonal method, although it may cause heavier or more painful menstrual bleeding.

Etonogestrel implant

The implant is a highly effective progestin-only method. Irregular bleeding is one of the most important counseling points.

The PID board trap

A history of pelvic inflammatory disease does not automatically disqualify a patient from receiving an IUD.

Current PID is a contraindication to initiating an IUD, but previous PID that has been appropriately treated is not an absolute contraindication. A patient who develops PID while using an IUD does not routinely need immediate IUD removal; the infection should be treated and the patient followed closely.

Patients with current purulent cervicitis or active gonorrhea or chlamydia should not undergo IUD placement. However, patients who need STI screening may usually be screened on the day of insertion without delaying placement while awaiting results, provided there is no known current infection or purulent cervicitis.

Board pearl

“Previous PID” and “current PID” are not interchangeable. Read the timeline in the question carefully.

Emergency Contraception: Know the Method, Timing, and Follow-Up

Emergency contraception questions test more than the number of hours since intercourse. You may also need to consider body weight, access, drug interactions, the desire for ongoing contraception, and when regular hormonal contraception can be restarted.

Copper IUD

The copper IUD is the most effective established form of emergency contraception and may generally be inserted within five days of the first episode of unprotected intercourse. It also provides ongoing contraception after insertion.

Ulipristal acetate

Ulipristal acetate can be taken within five days of unprotected intercourse and is generally more effective than levonorgestrel later in the five-day window.

Because ulipristal has antiprogestin effects, the patient should generally wait at least five days before starting or restarting a progestin-containing hormonal contraceptive. Starting hormonal contraception too soon may reduce ulipristal’s effectiveness.

Levonorgestrel emergency contraception

Levonorgestrel should be taken as soon as possible. It can be used within five days, but effectiveness decreases as time passes.

Unlike ulipristal, regular hormonal contraception may be started or resumed immediately after levonorgestrel emergency contraception. Backup contraception is still needed for the recommended interval.

High-Yield Contraception Comparison

Method	Board-exam advantage	High-yield caution
Combined hormonal contraception	Cycle control and effective ovulation suppression	Avoid with migraine with aura and major estrogen-related risks
Traditional progestin-only pill	Appropriate when estrogen is contraindicated	More than three hours late is considered missed
Drospirenone progestin-only pill	Wider missed-pill window	Distinguish its instructions from traditional POPs
DMPA	No daily adherence	Bone mineral density warning and delayed fertility return
Levonorgestrel IUD	Long-acting and may reduce bleeding	Do not insert with current PID, cervicitis, gonorrhea, or chlamydia
Copper IUD	Hormone-free and effective emergency contraception	May increase menstrual bleeding or cramping
Implant	Highly effective and estrogen-free	Unpredictable bleeding is common

Cervical Cancer Screening for FNP Boards

Cervical cancer screening questions become easier when you identify four things:

The patient’s age
Whether the cervix is still present
Previous screening results
Whether the patient is average risk or high risk

As of July 2026, the current final USPSTF recommendation includes the following screening options for average-risk patients.

Ages 21 to 29

Perform cervical cytology alone every three years.

Routine HPV testing is not the standard screening method for this age group under the current final USPSTF recommendation because transient HPV infections are common.

Ages 30 to 65

Acceptable options include:

Cervical cytology alone every three years
Primary high-risk HPV testing alone every five years
High-risk HPV testing combined with cytology every five years

The original version of this article omitted primary HPV testing alone, which is an important screening option for patients ages 30 through 65.

Older than 65

Screening may be discontinued when the patient has had adequate previous negative screening, is not otherwise at high risk, and has no history requiring continued surveillance.

Do not stop screening solely because a patient turned 65 without first confirming the screening history.

After a hysterectomy

Do not automatically answer, “No more Pap smears.”

First determine:

Was the cervix removed?
Was the hysterectomy performed for a benign condition?
Is there a history of high-grade cervical precancer or cervical cancer?

Patients who had a total hysterectomy with removal of the cervix for a benign reason and have no relevant high-grade history generally do not require routine cervical cancer screening.

Does HPV vaccination eliminate screening?

No.

Patients who received the HPV vaccine should continue cervical cancer screening according to the recommended schedule. The vaccine substantially reduces risk but does not protect against every oncogenic HPV type or eliminate the possibility of previous exposure.

Board pearl

Never choose a cervical screening answer based only on sexual activity or HPV vaccination status. The patient’s age, cervix status, screening history, and risk factors determine the plan.

Breast Cancer Screening for FNP Boards

For average-risk women, the 2024 USPSTF recommendation is screening mammography every two years from age 40 through age 74.

For women age 75 and older, the USPSTF states that current evidence is insufficient to determine the balance of benefits and harms. This does not mean every patient must stop screening on her 75th birthday. It means the decision requires individualized consideration rather than a universal USPSTF recommendation.

Why breast screening questions can be confusing

Different professional organizations have historically recommended different starting ages and intervals. A well-written board question may:

Identify the guideline being used
Focus on the USPSTF recommendation
Present a patient who is not average risk
Ask about diagnostic evaluation rather than routine screening

A patient with a new breast mass, nipple retraction, unilateral bloody discharge, skin dimpling, or other concerning symptom needs diagnostic evaluation. That is not the same clinical pathway as routine screening mammography.

Board pearl

Do not confuse a screening mammogram for an asymptomatic patient with a diagnostic evaluation for a new symptom or abnormal finding.

STI Screening: What FNP Students Must Know

Many sexually transmitted infections are asymptomatic, so a normal pelvic examination does not eliminate the need for screening.

Chlamydia and gonorrhea

Screen annually for chlamydia and gonorrhea in:

All sexually active women younger than 25
Women age 25 or older who have increased risk, such as a new sexual partner, multiple partners, a partner with an STI, or inconsistent condom use outside a mutually monogamous relationship

Screening at exposed anatomic sites should also be considered based on the patient’s sexual practices.

HIV screening

CDC guidance recommends at least one HIV test for everyone between ages 13 and 64, with repeat testing for patients who have ongoing risk.

STI screening during pregnancy

Every pregnancy should include early screening for:

HIV
Syphilis
Hepatitis B
Hepatitis C

Pregnant patients younger than 25 should also be screened for chlamydia and gonorrhea. Pregnant patients age 25 or older should be screened when increased risk is present. Some patients require repeat testing during the third trimester based on age, risk, community prevalence, or state requirements.

Important correction

Hepatitis C screening during pregnancy is no longer limited only to patients with traditional risk factors. CDC recommends hepatitis C screening during each pregnancy, except in settings where the prevalence of infection is exceptionally low.

Menopause Management for FNP Boards

Menopause is diagnosed after 12 consecutive months without menstruation when amenorrhea is not explained by pregnancy, medication, another medical condition, or a surgical cause.

Common symptoms include:

Hot flashes
Night sweats
Sleep disruption
Vaginal dryness
Dyspareunia
Urinary symptoms
Mood or concentration changes
Changes in menstrual frequency during the menopausal transition

The key board question is usually not whether the patient is experiencing menopause. It is whether she needs systemic treatment, local treatment, a nonhormonal option, or additional evaluation for another diagnosis.

Systemic hormone therapy

Systemic hormone therapy is the most effective treatment for bothersome vasomotor symptoms such as hot flashes and night sweats. For many healthy symptomatic patients younger than 60 or within 10 years of menopause onset, the benefit-risk profile is generally favorable when no contraindications are present. Treatment should be individualized rather than automatically limited to an arbitrary number of years.

Patient without a uterus

A patient who has undergone hysterectomy may generally use estrogen without a progestogen, assuming no other contraindications are present.

Patient with a uterus

A patient with an intact uterus generally requires a progestogen with systemic estrogen to protect the endometrium from hyperplasia and endometrial cancer.

This is one of the most frequently tested menopause principles:

Uterus present = protect the endometrium.

Who should generally avoid systemic hormone therapy?

Systemic hormone therapy is generally not appropriate for patients with conditions such as:

Breast cancer
Uterine cancer
Unexplained uterine bleeding
Active or significant liver disease
Previous blood clots
Certain cardiovascular or cerebrovascular diseases

The decision depends on the patient’s complete history, the type and route of therapy, symptom severity, and specialist input when appropriate.

Genitourinary syndrome of menopause

Genitourinary syndrome of menopause may cause:

Vaginal dryness
Burning or irritation
Dyspareunia
Urinary urgency
Recurrent urinary symptoms

Patients whose symptoms are limited to the vagina or urinary tract may not need systemic hormone therapy.

Low-dose vaginal estrogen provides effective local treatment with substantially less systemic exposure than systemic hormone therapy. However, patients with a history of estrogen-sensitive cancer require individualized shared decision-making and, in some cases, consultation with their oncology team.

Nonhormonal treatment for hot flashes

Evidence-supported nonhormonal prescription options include:

Certain SSRIs
Certain SNRIs
Gabapentin
Oxybutynin
Fezolinetant

Paroxetine mesylate and fezolinetant are FDA-approved specifically for menopausal vasomotor symptoms. Treatment selection should reflect the patient’s other diagnoses, medications, adverse-effect risks, and preferences.

Board pearl

Do not automatically prescribe systemic estrogen for vaginal dryness alone. When symptoms are localized, think about localized treatment.

Ten Women’s Health Board Traps to Remember

Migraine with aura is a contraindication to combined hormonal contraception.
Smoking after age 35 should push you away from estrogen-containing contraception, particularly with heavier smoking.
A previous history of PID is not the same as current PID.
Do not insert an IUD in a patient with known current gonorrhea, chlamydia, purulent cervicitis, or current PID.
Traditional and drospirenone progestin-only pills have different missed-pill rules.
Wait at least five days before restarting progestin-containing hormonal contraception after ulipristal.
HPV vaccination does not eliminate cervical cancer screening.
After hysterectomy, determine whether the cervix was removed and why the surgery was performed.
A patient with a uterus generally needs progestogen protection when using systemic estrogen.
Under the USPSTF guideline, average-risk mammography begins at age 40 and occurs every two years through age 74.

Test Your Knowledge: Women’s Health FNP Board Questions

Question 1

A 29-year-old patient with migraine with aura requests combined oral contraception. Her blood pressure is normal, and she does not smoke.

What is the most appropriate response?

Answer: Avoid combined hormonal contraception and discuss a progestin-only or nonhormonal method.

Why: Migraine with aura is a contraindication to estrogen-containing contraception because of the increased risk of ischemic stroke.

Question 2

A 27-year-old patient had PID four years ago. She completed treatment and has had no recurrence. She requests an IUD.

What is the best response?

Answer: Previous treated PID does not automatically prevent IUD use. Assess current STI risk and symptoms, provide appropriate screening, and proceed if no current contraindication is present.

Question 3

A 34-year-old average-risk patient asks how often she needs cervical cancer screening.

Which options are acceptable under the current final USPSTF recommendation?

Answer: Cytology every three years, primary high-risk HPV testing every five years, or HPV and cytology cotesting every five years.

Question 4

A 52-year-old patient with an intact uterus has severe hot flashes and no contraindications to hormone therapy.

Which regimen protects against endometrial hyperplasia?

Answer: Systemic estrogen combined with an appropriate progestogen.

Question 5

A patient takes ulipristal for emergency contraception and wants to restart her combined oral contraceptive that evening.

What should she be told?

Answer: Wait at least five days before restarting hormonal contraception because the progestin may reduce ulipristal’s effectiveness. Use barrier protection according to the recommended instructions.

Frequently Asked Questions About Women’s Health on the FNP Boards

Is women’s health tested on both the AANP and ANCC FNP exams?

Yes. Both examinations assess the evaluation and management of patients across the lifespan, including reproductive health, preventive screening, contraception, sexually transmitted infections, pregnancy-related care, and menopause.

What contraception contraindication should I remember first?

Migraine with aura is one of the highest-yield contraindications to combined hormonal contraception. Also assess smoking after age 35, severe hypertension, thromboembolic history, current breast cancer, and major cardiovascular risk.

Can a patient with a history of PID receive an IUD?

Generally, yes. A remote, appropriately treated history of PID is not an absolute contraindication. Current PID, purulent cervicitis, gonorrhea, or chlamydia is a contraindication to initiating IUD placement.

What is the most effective established emergency contraception?

The copper IUD is the most effective established emergency contraceptive method and also provides ongoing contraception.

Does an HPV-vaccinated patient still need cervical cancer screening?

Yes. HPV vaccination does not eliminate the need for age-appropriate cervical cancer screening.

At what age does routine mammography begin?

Under the 2024 USPSTF recommendation, average-risk women should receive screening mammography every two years from age 40 through age 74.

Does every menopausal patient need hormone therapy?

No. Treatment depends on symptom type, severity, medical history, risk factors, and patient preferences. Local symptoms may respond to local therapy, while vasomotor symptoms may be treated with systemic hormone therapy or evidence-supported nonhormonal medications.

Stop Memorizing Lists. Start Practicing Clinical Decisions.

Women’s health questions become much easier when you stop treating contraception, screening, and menopause as separate lists of facts.

Instead, ask:

What makes this patient different?
Which option creates the least risk?
Is this screening or diagnostic evaluation?
Is the condition current or historical?
Are the symptoms systemic or localized?
What detail in the question changes the answer?

The FNP Review is designed to help you develop that kind of clinical pattern recognition. With more than 280 review lectures, over 2,900 board-style questions, practice exams, pharmacology flashcards, and a personalized study calendar, you can move beyond memorization and begin practicing the decisions the boards actually expect you to make.

You do not need to study everything at once. You need to recognize the patterns, understand why an answer is safest, and practice until those decisions feel familiar.

Start your FNP board preparation with The FNP Review and walk into your AANP or ANCC exam with a clear plan.

Suggested CTA Button: Start Your FNP Board Review

Educational note: Screening, treatment, and contraceptive guidelines change over time. This article is intended for board-review education and does not replace individualized medical care or the complete recommendations of the relevant professional organization.